Lipid disorders are one of the most important metabolic disorders that mankind is struggling with. Statins are introduced into the market which has been a real boon for many to overcome or to manage lipid disorders. But improper diet, sedentary life style and many factors are still taking its toll. As of now statins are considered to be the best option to manage elevated LDL-C or total cholesterol levels. And when it comes to elevated triglycerides Fibrates play a crucial role in lowering the risk. As a first line therapy in hypercholesterolemia and Hypertriglyceridemia , statins and Fibrates lowers the risk factors effectively. But for management of lipids in the long run these drugs may cause concern because of their adverse effect profile. The adverse effects profile may bother a practitioner in case of dose escalation. As the adverse effects like myalgia, elevated liver enzymes and libido are more profusely seen in patients during dose escalation. But statins are considered to be the gold standard in cholesterol management. So to avoid the adverse effects as well as maximize the lipid lowering efficacy Grandix is the first company in the globe to come out with a concept of Maxitor combipack.
Maxitor is a combipack which contains 1 soft gelatin capsule of omega 3 fatty acids( 18% EPA&12% DHA) 1 tablet of Policosanol and 1 soft gelatin capsule of phytosterol.
Omega 3 fatty acids
Reduce inflammation and help prevent risk factors associated with chronic diseases such as heart disease. Clinical evidence suggests that EPA and DHA found in fish oil help reduce risk factors for heart disease including high cholesterol and high blood pressure. There is also strong evidence that these substances can help prevent and treat atherosclerosis by inhibiting the development of plaque and blood clots, each of which tends to clog arteries. Clinical studies of heart attack survivors have found that daily omega-3 fatty acid supplements dramatically reduce the risk of death, subsequent heart attacks, and stroke.
Policosanol
Policosanol produces a significant reduction of serum total cholesterol and LDL-C levels. HDL-C values were also increased. Polycosanol safely lowered total cholesterol by 17.5% and LDL cholesterol
21.8%. Produces cholesterol-lowering effects within the first 6 to 8 weeks of use.
Phytosterol
Intake of phytosterol prevents cholesterol resorption. This results in lowering of blood cholesterol to a basal endogenous levels. As per AJCN phytosterols have important effects on cholesterol absorption and metabolism .
Maxitor is a combipack which contains 1 soft gelatin capsule of omega 3 fatty acids( 18% EPA&12% DHA) 1 tablet of Policosanol and 1 soft gelatin capsule of phytosterol.
Omega 3 fatty acids
Reduce inflammation and help prevent risk factors associated with chronic diseases such as heart disease. Clinical evidence suggests that EPA and DHA found in fish oil help reduce risk factors for heart disease including high cholesterol and high blood pressure. There is also strong evidence that these substances can help prevent and treat atherosclerosis by inhibiting the development of plaque and blood clots, each of which tends to clog arteries. Clinical studies of heart attack survivors have found that daily omega-3 fatty acid supplements dramatically reduce the risk of death, subsequent heart attacks, and stroke.
Policosanol
Policosanol produces a significant reduction of serum total cholesterol and LDL-C levels. HDL-C values were also increased. Polycosanol safely lowered total cholesterol by 17.5% and LDL cholesterol
21.8%. Produces cholesterol-lowering effects within the first 6 to 8 weeks of use.
Phytosterol
Intake of phytosterol prevents cholesterol resorption. This results in lowering of blood cholesterol to a basal endogenous levels. As per AJCN phytosterols have important effects on cholesterol absorption and metabolism .
Maxitor is a combination of omega 3 fatty acids 1000 mg policosanol 10 mg & phytosterol 200 mg in a combi packA mechanism to explain the hypotriglyceridemic effects of marine omega-3 fatty acids in humans has not been clarified. A working model can be developed at the gene transcriptional level, which involves >or=4 metabolic nuclear receptors. These include liver X receptor, hepatocyte nuclear factor-4alpha (HNF-4alpha), farnesol X receptor, and peroxisome proliferator-activated receptors (PPARs). Each of these receptors is regulated by sterol receptor element binding protein-1c (SREBP-1c), the main genetic switch controlling lipogenesis. Omega-3 fatty acids elicit hypotriglyceridemic effects by coordinately suppressing hepatic lipogenesis through reducing levels of SREBP-1c, upregulating fatty oxidation in the liver and skeletal muscle through PPAR activation, and enhancing flux of glucose to glycogen through downregulation of HNF-4alpha. The net result is the repartitioning of metabolic fuel from triglyceride storage toward oxidation, thereby reducing the substrate available for very-low-density lipoprotein (VLDL) synthesis. By simultaneously downregulating genes encoding proteins that stimulate lipid synthesis and upregulating genes encoding proteins that stimulate fatty acid oxidation, omega-3 fatty acids are more potent hypotriglyceridemic agents than are omega-6 fatty acids, on a carbon-for-carbon basis. Additionally, peroxidation of omega-3 fatty acids may reduce VLDL secretion through stimulating apolipoprotein B degradation. Omega-3 fatty acids may act by enhancing postprandial chylomicron clearance through reduced VLDL secretion and by directly stimulating lipoprotein lipase activity. These combined effects support the use of omega-3 fatty acids as a valuable clinical tool for the treatment of hypertriglyceridemia.
